This randomized clinical trial evaluates the efficacy and safety of adjuvant trastuzumab continued beyond chemotherapy for a duration of 9 weeks vs 1 year in women with HER2-positive early breast cancer treated with up-front chemotherapy containing a taxane and trastuzumab.
https://ift.tt/2JlBHeH
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
http://bit.ly/2SylJiJ
-
Publication date: Available online 22 March 2017 Source: Medical Journal Armed Forces India Author(s): S.C. Shaw, M.S. Vinod, Amit Devgan ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου